GLG 801

Drug Profile

GLG 801

Alternative Names: GLG-801

Latest Information Update: 04 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute
  • Developer GLG Pharma
  • Class Antineoplastics; Small molecules; Urologics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Preclinical Polycystic kidney disease

Most Recent Events

  • 20 Nov 2015 Phase-II clinical trials in Chronic lymphocytic leukaemia (Combination therapy) in Poland (PO) prior to November 2015
  • 20 Nov 2015 Preclinical trials in Polycystic kidney disease in Poland (unspecified) prior to November 2015
  • 20 Nov 2015 GLG Pharma plans phase I trials for Polycystic kidney disease in Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top